Dariohealth CORP. (DRIO) — SEC Filings

Overview

Dariohealth CORP. (DRIO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEF 14A filed on Dec 22, 2025: DarioHealth Corp. (DRIO) is holding its Annual Meeting of Stockholders on January 29, 2026, to address several key proposals. Shareholders will vote on the re-election of seven directors, including CEO Erez Raphael, for a one-year term expiring at the 2027 Annual Meeting. A significant proposal invo

Sentiment Summary

Across 47 filings, the sentiment breakdown is: 6 bearish, 38 neutral, 3 mixed. The dominant filing sentiment for Dariohealth CORP. is neutral.

Filing Type Overview

Dariohealth CORP. (DRIO) has filed 30 8-K, 5 DEF 14A, 6 10-Q, 2 10-K, 2 SC 13G, 2 SC 13G/A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (47)

• 8-K Filing — 8-K · Apr 13, 2026
• DarioHealth Seeks Shareholder Approval for Director Re-election, Equity Raises — DEF 14A · Dec 22, 2025 Risk: medium
  DarioHealth Corp. (DRIO) is holding its Annual Meeting of Stockholders on January 29, 2026, to address several key proposals. Shareholders will vote on the re-e
• DarioHealth Narrows Losses Amid Revenue Dip, Boosts Cash Reserves — 10-Q · Nov 13, 2025 Risk: high
  DarioHealth Corp. reported a total revenue of $5.007 million for the three months ended September 30, 2025, a decrease from $7.423 million in the same period of
• 8-K Filing — 8-K · Nov 10, 2025
• DarioHealth Corp. Files 8-K with Key Agreements and Equity Sales — 8-K · Sep 25, 2025 Risk: medium
  DarioHealth Corp. filed an 8-K on September 25, 2025, reporting on several key events. These include entering into a material definitive agreement, unregistered
• DarioHealth Corp. Files 8-K: Corporate Updates — 8-K · Sep 19, 2025 Risk: medium
  On September 18, 2025, DarioHealth Corp. filed an 8-K report detailing material modifications to the rights of security holders and amendments to its articles o
• DarioHealth Corp. Files 8-K — 8-K · Sep 12, 2025 Risk: medium
  DarioHealth Corp. filed an 8-K on September 12, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, d
• DarioHealth Corp. Files 8-K — 8-K · Aug 25, 2025 Risk: low
  DarioHealth Corp. filed an 8-K on August 25, 2025, reporting amendments to its articles of incorporation or bylaws, other events, and financial statements/exhib
• DarioHealth Q2 Loss Widens to $12.12M Despite 18.5% Revenue Jump — 10-Q · Aug 12, 2025 Risk: high
  DarioHealth Corp. reported a net loss of $12.12 million for the quarter ended June 30, 2025, a significant increase from the $10.47 million net loss in the prio
• DarioHealth Corp. Files 8-K on Shareholder Vote Matters — 8-K · Jul 23, 2025 Risk: low
  DarioHealth Corp. filed an 8-K on July 23, 2025, reporting on matters submitted to a vote of its security holders. The filing does not contain details about the
• DarioHealth Corp. Files 8-K: Leadership and Compensation Changes — 8-K · Jul 10, 2025 Risk: medium
  On July 10, 2025, DarioHealth Corp. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates a shift in
• DarioHealth Seeks Reverse Stock Split, Board Re-election — DEF 14A · May 30, 2025 Risk: medium
  DarioHealth Corp. (DRIO) filed a DEF 14A on May 30, 2025, outlining proposals for its Annual Meeting on July 23, 2025. Key proposals include the re-election of
• DarioHealth Corp. Files 8-K: Material Agreements & Equity Changes — 8-K · May 29, 2025 Risk: medium
  DarioHealth Corp. filed an 8-K on May 29, 2025, reporting on events that occurred on May 23, 2025. The filing indicates DarioHealth Corp. entered into a Materia
• DarioHealth Corp. Files 8-K with Bylaw Amendments — 8-K · May 21, 2025 Risk: low
  DarioHealth Corp. filed an 8-K on May 20, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, formerly
• DarioHealth Reports Q1 2025 Financials, Equity Issuances — 10-Q · May 14, 2025 Risk: medium
  DarioHealth Corp. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $42.7 million and total liabilities of $38.4 million
• DarioHealth Corp. Files 8-K on Material Agreements — 8-K · May 6, 2025 Risk: medium
  On April 30, 2025, DarioHealth Corp. entered into a material definitive agreement, likely related to financing or operations, as indicated by the filing of an 8
• DarioHealth Corp. Files 8-K on Shareholder Votes — 8-K · Apr 28, 2025 Risk: low
  DarioHealth Corp. filed an 8-K on April 28, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain details about th
• DarioHealth Corp. Files 8-K on Director Changes and Compensation — 8-K · Apr 21, 2025 Risk: medium
  DarioHealth Corp. filed an 8-K on April 21, 2025, reporting on the departure of directors, election of new directors, and compensatory arrangements for officers
• DarioHealth Corp. Faces Delisting Notice — 8-K · Mar 19, 2025 Risk: high
  DarioHealth Corp. filed an 8-K on March 19, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company, forme
• DarioHealth Corp. Announces Board and Executive Changes — 8-K · Mar 14, 2025 Risk: medium
  DarioHealth Corp. announced on March 12, 2025, changes in its board and executive team, including the departure of certain officers and directors, the election
• DarioHealth Corp. Files Definitive Proxy Statement — DEF 14A · Mar 10, 2025 Risk: low
  DarioHealth Corp. filed its definitive proxy statement on March 10, 2025, for its annual meeting on April 28, 2025. The filing details information related to th
• DarioHealth Corp. 2024 10-K: Assets $27.2M, Liabilities $38.4M — 10-K · Mar 10, 2025 Risk: medium
  DarioHealth Corp. filed its 2024 10-K on March 10, 2025, reporting total assets of $27.2 million and total liabilities of $38.4 million for the fiscal year endi
• DarioHealth Corp. Announces Board Changes and Executive Compensation Updates — 8-K · Feb 27, 2025 Risk: medium
  DarioHealth Corp. announced on February 24, 2025, a change in its board of directors, including the departure of certain officers and the election of new direct
• DarioHealth Corp. Files 8-K — 8-K · Jan 22, 2025 Risk: low
  DarioHealth Corp. filed an 8-K on January 22, 2025, reporting an event that occurred on January 21, 2025. The filing indicates "Other Events" and "Financial Sta
• DarioHealth Corp. Files 8-K: Material Agreement & Equity Sales — 8-K · Jan 10, 2025 Risk: medium
  DarioHealth Corp. announced on January 7, 2025, that it entered into a material definitive agreement and also disclosed unregistered sales of equity securities.
• DarioHealth Corp. Files 8-K on Shareholder Votes — 8-K · Dec 18, 2024 Risk: low
  DarioHealth Corp. filed an 8-K on December 18, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific deta
• SC 13G Filing — SC 13G · Dec 13, 2024
• DarioHealth Q3 2024: Assets $31.3M, Liabilities $27.2M — 10-Q · Nov 7, 2024 Risk: medium
  DarioHealth Corp. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $31.32 million and total liabilities of $27.19 m
• SC 13G Filing — SC 13G · Oct 29, 2024
• DarioHealth Files Definitive Proxy Statement — DEF 14A · Oct 24, 2024 Risk: low
  DarioHealth Corp. filed its definitive proxy statement on October 24, 2024, for its annual meeting on December 18, 2024. The company, formerly known as LabStyle
• DarioHealth Faces Nasdaq Listing Rule Violation — 8-K · Sep 20, 2024 Risk: high
  DarioHealth Corp. received a notice on September 16, 2024, indicating it failed to meet a continued listing rule or standard for the Nasdaq Capital Market. The
• DarioHealth Corp. Files 8-K on Security Holder Rights — 8-K · Sep 13, 2024 Risk: medium
  DarioHealth Corp. filed an 8-K on September 13, 2024, reporting material modifications to the rights of security holders and amendments to its articles of incor
• DarioHealth Reports Q2 2024 Results — 10-Q · Aug 8, 2024 Risk: medium
  DarioHealth Corp. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $30.02 million and total liabilities of $2.72 million
• DarioHealth Corp. Files 8-K on Governance Changes — 8-K · Jun 28, 2024 Risk: medium
  DarioHealth Corp. filed an 8-K on June 28, 2024, reporting material modifications to the rights of security holders and amendments to its articles of incorporat
• DarioHealth Corp. Announces Corporate Changes and Filings — 8-K · Jun 25, 2024 Risk: medium
  DarioHealth Corp. announced on June 25, 2024, a series of significant corporate actions. These include the departure of certain officers and directors, the elec
• DarioHealth Appoints New Directors, Discloses Officer Compensation — 8-K · Jun 5, 2024 Risk: medium
  DarioHealth Corp. announced on June 5, 2024, the appointment of Dr. David J. Shulkin as a new director and the election of Ms. Sarah E. Shulkin as a director. T
• DarioHealth Corp. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk: low
  DarioHealth Corp. (DRIO) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. DarioHealth Corp. filed a 10-Q report for the period ending March 31, 202
• DarioHealth Corp. Announces Special Meeting of Stockholders on June 25, 2024 — DEF 14A · May 1, 2024 Risk: medium
  DarioHealth Corp. (DRIO) filed a Proxy Statement (DEF 14A) with the SEC on May 1, 2024. Special meeting of stockholders to be held on June 25, 2024, at 9:00 a.m
• DarioHealth Completes Asset Acquisition — 8-K · Apr 22, 2024 Risk: medium
  DarioHealth Corp. reported on April 22, 2024, the completion of its acquisition of certain assets from a subsidiary of a private company on February 15, 2024. T
• DarioHealth Corp. Relocates Principal Executive Offices — 8-K · Apr 19, 2024 Risk: low
  DarioHealth Corp. filed an 8-K on April 19, 2024, reporting a change in its principal executive offices to 322 W 57th St, #33B, New York, NY 10019, effective Ap
• DarioHealth Corp. Board Changes and Officer Compensation — 8-K · Apr 5, 2024 Risk: low
  DarioHealth Corp. announced on April 4, 2024, a change in its board of directors. Specifically, Ms. Yaffa Bar-On has been appointed as a new director, and Mr. Y
• DarioHealth Corp. Files 2023 Annual Report on Form 10-K — 10-K · Mar 28, 2024 Risk: medium
  DarioHealth Corp. (DRIO) filed a Annual Report (10-K) with the SEC on March 28, 2024. DarioHealth Corp. filed its 2023 Form 10-K on March 28, 2024. The company
• DarioHealth Corp. Files 8-K — 8-K · Mar 1, 2024 Risk: low
  DarioHealth Corp. filed an 8-K on March 1, 2024, to report other events. The company, formerly known as LabStyle Innovations Corp., is incorporated in Delaware
• DarioHealth Files Routine 8-K on Feb 22, 2024 — 8-K · Feb 22, 2024 Risk: low
  DarioHealth Corp. filed an 8-K on February 22, 2024, disclosing information under Regulation FD and regarding Financial Statements and Exhibits. The filing indi
• DarioHealth Corp. Reports Material Agreements, Equity Sales, and Officer Changes — 8-K · Feb 21, 2024 Risk: medium
  DarioHealth Corp. filed an 8-K on February 21, 2024, reporting events from February 15, 2024. The filing indicates the company entered into a material definitiv
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Y.D. More Investments Amends DarioHealth (DRIO) Stake — SC 13G/A · Feb 6, 2024
  Y.D. More Investments Ltd. filed an amended Schedule 13G/A on February 6, 2024, indicating their ownership in DarioHealth Corp. (NASDAQ: DRIO) as of December 31

Risk Profile

Risk Assessment: Of DRIO's 41 recent filings, 4 were flagged as high-risk, 24 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Dariohealth CORP.'s most recent 10-Q filing (Nov 13, 2025):

• Revenue: $17.128M
• Net Income: -$32.683M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $31.907M
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Erez Raphael
• Hila Karah
• Dennis Matheis
• Dennis M. McGrath
• Yoav Shaked
• Lawrence Leisure
• Adam K. Stern
• Hamas
• Dr. David J. Shulkin
• Ms. Sarah E. Shulkin
• Yaffa Bar-On
• Yishai Klein

Industry Context

DarioHealth operates in the digital health sector, focusing on remote patient monitoring and chronic disease management. This industry is characterized by rapid technological advancement, increasing adoption of telehealth solutions, and a growing demand for personalized healthcare. Key trends include the integration of AI and machine learning for data analysis, the expansion of value-based care models, and evolving reimbursement policies for digital health services.

Top Tags

corporate-governance (10) · financials (6) · material-agreement (5) · filing (5) · equity-sale (4) · 8-K (4) · governance (4) · 10-Q (3) · shareholder-vote (3) · corporate-action (3)

Key Numbers

• Common Stock shares: 1,697,843 — Issued from Series D, D-1, D-2, D-3 Preferred Stock conversion in private placements
• Shares: 500,000 — Proposed increase to the 2020 Equity Incentive Plan
• Reverse stock split: 20-for-1 — Effected on August 28, 2025
• Date: December 18, 2024 — Closure of first private placement transaction
• Total revenues (Q3 2025): $5.007M — Decreased from $7.423M in Q3 2024, a 32.5% decline.
• Total revenues (9M 2025): $17.128M — Decreased from $19.436M in 9M 2024, a 11.9% decline.
• Net loss (Q3 2025): $10.466M — Improved from $12.330M in Q3 2024, a 15.1% reduction.
• Net loss (9M 2025): $32.683M — Slightly improved from $33.115M in 9M 2024, a 1.3% reduction.
• Total operating expenses (9M 2025): $37.954M — Decreased from $55.141M in 9M 2024, a 31.2% reduction.
• Cash and cash equivalents (Sept 30, 2025): $31.907M — Increased from $27.764M at Dec 31, 2024.
• Net cash provided by financing activities (9M 2025): $24.332M — Significant increase from $20.206M in 9M 2024, bolstering cash reserves.
• Net cash used in operating activities (9M 2025): $20.054M — Improved from $31.830M in 9M 2024, but still a substantial cash burn.
• Reverse Stock Split Ratio: 20-for-1 — Effected on August 28, 2025, reducing outstanding shares.
• Common shares outstanding (Nov 11, 2025): 6,768,184 — Reflects the impact of the reverse stock split and subsequent issuances.
• Commission File Number: 001-37704 — Identifies the specific SEC filing for DarioHealth Corp.

Frequently Asked Questions